Veeva Systems FY26: $3B+ Cloud, $6B Target by FY30

Thesis

Veeva Systems (NYSE: VEEV) closed FY26 (January 2026) having crossed the $3 billion revenue milestone — revenue $3.195B (+16.3%), non-GAAP operating income $1.434B, GAAP EPS $5.44 (+25.9%), and FCF $1.386B (+29.6%). Operating margin expanded meaningfully as the company scaled without proportional cost growth. The balance sheet is pristine: $1.421B cash, $96M total debt, and virtually zero CapEx ($29M on $3.2B revenue). Management set a $6B FY30 (January 2030) revenue target — roughly 17% CAGR from FY26 — and announced Veeva's first-ever entry into horizontal CRM markets beyond life sciences.

Veeva is the dominant cloud software platform for the global life sciences industry (pharma, biotech, medical device). Its moat is unique among enterprise software companies: the regulatory environment of pharma and biotech imposes FDA/EMA validation requirements on every software platform used in the development, manufacturing, and commercialization of drugs. Switching a validated Veeva system requires re-validation — a 12-24 month process — at significant cost. This creates one of the stickiest customer bases in software.

The FY26-FY30 investment thesis has four concurrent growth vectors:

1. Vault CRM transition completed (primary risk resolved): Veeva's legacy CRM product was built on Salesforce. Vault CRM is built on Veeva's own cloud. The migration from Salesforce-dependent CRM to Vault CRM was the primary investor concern for 2022-2025 — any Salesforce disruption or migration friction could cause customer attrition. By Q4 FY26, 140+ bulk customers were live on Vault CRM; all 14 of 14 top-20 customers committed to migrate. The CRM transition risk is structurally behind Veeva.

2. Crossix commercial data: 30%+ growth continuing: Crossix is Veeva's life sciences data analytics business — providing de-identified patient data and measurement services to pharma commercial teams. Growing 30%+ YoY, Crossix is becoming a material revenue contributor and strengthens Veeva's commercial cloud ecosystem. The IQVIA lawsuit resolution (settled in FY26 Q2) removed restrictions on product development and data integration, unlocking new commercial cloud capabilities.

3. Vault expansion across clinical, quality, regulatory: Beyond CRM, Veeva's Vault platform covers clinical operations (eTMF, CTMS), quality management (QualityDocs, QMS), and regulatory submissions (RIM). Each Vault product is validated independently; once a customer validates one Vault product, adding the next has lower incremental switching friction. The cross-sell motion drives net revenue retention above 100%.

4. Veeva AI: long-term monetization building: Veeva is embedding AI capabilities across its product suite — eTMF Bot (automating document management), CRM Voice Control, and AI-assisted regulatory writing. Near-term revenue impact is limited, but AI capabilities strengthen product differentiation and create future premium pricing opportunities. The company is also developing AI-driven horizontal CRM to expand beyond life sciences.

FY26 Numbers vs FY25 (Annual, USD; January year-end)

Veeva crossed $3B revenue in calendar 2025 (per management's run-rate goal). GAAP operating margin of 28.7% is exceptional for a mid-growth enterprise SaaS company at this scale.

Business Model: Regulated Cloud for Life Sciences

Veeva's structural advantage is the intersection of software and pharmaceutical regulation:

Validated software = switching costs: The FDA and EMA require pharmaceutical companies to validate all computer systems involved in drug development, manufacturing, and commercialization. Validation means documenting that the software performs as intended under all operating conditions — a process requiring 6-18 months per system and significant IT/quality resources. When a drug manufacturer uses Veeva Vault for their clinical trial data (eTMF), switching to a competitor requires running a parallel validation of the new system — a major undertaking. No CFO approves unnecessary re-validation.

Cross-sell platform economics: Veeva builds multiple Vault products (eTMF, QMS, RIM, CTMS) on one cloud platform. Each new Vault product has a lower deployment cost than the first because the IT infrastructure, integration, and user training already exists. This creates a platform expansion dynamic: the more Vault products a customer uses, the more economical additional Vault products become, and the more prohibitive a multi-vendor strategy becomes.

Net revenue retention >100%: As customers add more products and expand seat counts, annual contract values grow without requiring new customer acquisition. This is the defining characteristic of Veeva's revenue quality.

Product Segments

Commercial Cloud (~55% of Revenue)

CRM products (Vault CRM + legacy CRM) for pharmaceutical sales forces, plus Crossix (commercial data analytics) and emerging data products.

Vault CRM migration: 140+ live bulk customers by Q4 FY26, all top-20 customers committed. CRM now ~20% of total revenue (from ~25% two years ago) as other segments grow faster. The Vault CRM migration from Salesforce-dependent architecture to Veeva's native cloud removes Salesforce's strategic leverage over Veeva's CRM product development and pricing.

Crossix at 30%+ growth: Provides de-identified patient claims data, physician-level targeting intelligence, and campaign measurement services to pharma commercial teams. Growing faster than the rest of Veeva and strengthening competitive differentiation in commercial cloud. The IQVIA lawsuit resolution opens new data integration opportunities.

R&D Cloud (~45% of Revenue)

Vault Clinical (eTMF, CTMS, Site Connect), Vault Quality (QualityDocs, QMS, LIMS), Vault Regulatory (RIM, Submissions), and Safety (pharmacovigilance).

Clinical: eTMF is Veeva's most penetrated Vault product globally — now expanding into broader clinical suite including CTMS and Study Training. International expansion continuing as non-US pharma companies adopt Vault.

Quality: LIMS (Laboratory Information Management System) expansion represents a significant upsell into quality lab workflows — a large TAM within existing customers.

Safety: Long sales cycles but AI (eTMF Bot, safety signal detection) could accelerate adoption. Safety software switching costs are among the highest in pharma IT.

Horizontal CRM initiative: Announced in FY26, Veeva is building CRM for industries outside life sciences — the first extension of the platform beyond pharma/biotech. A separate team and operating model reduces execution risk to the core business. If successful, horizontal CRM opens a market comparable in size to life sciences.

Q4 FY26 Beat and FY30 Target

Q4 FY26 delivered $836M in revenue, results ahead of guidance. Full-year non-GAAP operating income reached $1.434B. Management's $3 billion revenue run-rate goal for calendar 2025 was achieved.

The headline from the Q4 FY26 call: $6 billion FY30 revenue target. At $3.195B FY26 revenue, $6B by FY30 (ending January 2030) implies approximately 17% CAGR over four years — consistent with recent growth trajectory and achievable through continued cross-sell, Crossix scale, and new product launches.

Management also highlighted "annual normalized billings" as the preferred forward indicator (more stable than quarterly billings given contract timing variability), and noted they would provide billings guidance quarterly without giving formal quarterly revenue/EPS guidance.

FY27 Framework

• Revenue growth: 16-19% growth trajectory toward $6B FY30 target implies ~$3.7-3.8B FY27
• Operating margin: GAAP 28.7% in FY26 with potential for further expansion as growth leverages fixed cost base; non-GAAP operating margin approaching 45%
• FCF: $1.5-1.7B range at current conversion rates; nearly 100% FCF/revenue conversion
• Buybacks: First buybacks initiated in FY26 ($169.9M); likely to continue as cash builds
• Crossix growth: 30%+ trajectory continuing through FY27; becoming a 10%+ revenue segment
• Vault CRM transition: Largely behind by FY27; CRM headwinds from migration period clearing

Multi-Year Strategic Position

Life sciences software is non-cyclical: Drug development and commercialization spending is largely insensitive to macroeconomic cycles. Pharma companies spend on software to get drugs to market faster — this spending does not decline in recessions. VEEV's revenue has never declined year-over-year.

TAM expansion through adjacent validation domains: Veeva's platform can address any validated software need in life sciences — manufacturing execution systems (MES), laboratory data systems (LIMS), safety reporting, and eventually AI-assisted clinical operations. Each represents $500M-$2B in incremental TAM within Veeva's existing customer base.

$6B FY30 target is underpinned by existing customers: Most of the $6B pathway comes from cross-selling additional Vault products to existing customers, not from acquiring new logos. At the current cross-sell pace, Veeva's FY30 target relies primarily on deepening penetration within the existing pharma/biotech customer base — a higher-quality growth source than net new customer acquisition.

Horizontal CRM as optionality, not dependency: The horizontal CRM initiative is managed as a separate team and operating model — a skunkworks approach that doesn't distract the core life sciences business. If it succeeds, the TAM expands dramatically. If it fails, the core business is unaffected.

Balance sheet provides strategic flexibility: $1.421B cash, $96M debt, $1.4B FCF generation. No leverage, no dilutive acquisitions required. Capital can be deployed for buybacks, tuck-in acquisitions, or horizontal CRM investment — all options are open.

Risks

• Vault CRM attrition from six at-risk customers: Management flagged potential attrition from approximately six customers during the Vault CRM migration; while not expected to be material in FY26-FY27, these situations could reduce net revenue retention temporarily
• Salesforce competitive response in CRM: Now that Veeva is migrating away from Salesforce infrastructure, Salesforce has incentive to develop competing life sciences CRM solutions or partner with competitors; competition in CRM is intensifying
• Pharma R&D budget pressure: If large pharma companies cut R&D spending (patent cliff, pipeline failures, price controls), clinical software renewal cycles could slow or platform spend could be deferred
• Crossix data privacy regulation: De-identified patient data businesses face increasing regulatory scrutiny; changes to HIPAA, state privacy laws, or international data regulations could constrain Crossix's data sourcing and use
• Horizontal CRM execution risk: The horizontal CRM initiative targets a mature, competitive market (Salesforce, HubSpot, Microsoft) — Veeva has no competitive moat outside life sciences, and the initiative could distract management
• Revenue growth deceleration below 15%: At $3.2B+ scale, maintaining 16-17% growth requires continuous product innovation and international expansion; any slowdown toward low-single-digit growth would compress the premium multiple
• Macro impact on small/mid biotech customers: Smaller biotech customers (dependent on VC and public capital markets funding) are vulnerable to funding squeezes; if biotech funding contracts, customer additions slow and Veeva's growth moderates

Citations

• VEEV FY26 financial statements (drillr financial_statements; period_end 2026-01 FY)
• VEEV FY25 financial statements (drillr financial_statements; period_end 2025-01 FY)
• Q4 FY26 earnings call (~2026-03): Revenue $836M Q4; full-year $3.195B; non-GAAP OI $1.434B; results ahead of guidance; $6B FY30 revenue target; 140+ live bulk Vault CRM customers; Vault CRM transition substantially complete; first share buybacks $169.9M; annual normalized billings as forward indicator
• Q3 FY26 earnings call (~2025-12): Revenue $811M +above guide; Veeva AI excellent progress; CRM 20% of revenue; Crossix strong; top-20 customers committed to Vault CRM
• Q2 FY26 earnings call (~2025-09): Revenue $789M; IQVIA lawsuit resolved; Veeva AI transformative potential; $6B revenue target on track; Crossix broad-based strength
• Q1 FY26 earnings call (~2025-06): Revenue $759M; $3B run-rate achieved in calendar 2025; Vault CRM 80+ live customers; Crossix 30%+ YoY; full-year guidance 19% growth; horizontal CRM initiative announced